Axovia Therapeutics

Developing therapies targeting ciliopathies.

Axovia is dedicated to developing disease-transformative therapies that target key aspects of ciliopathies, addressing the devastating impact of the disease head-on for patients, their families and caregivers.

Ciliopathies are a group of more than 55 rare inherited genetic diseases linked to more than 950 genes that impact the function of cilia, microscopic finger-like appendages that sit atop most cells in the body.

Those with ciliopathic symptoms generally experience a “rare disease odyssey” where these patients report having waited 5-30 years for the correct diagnosis, with the initial diagnosis being incorrect in 40% of cases.

Their lead development program focus is on Bardet-Biedl Syndrome (BBS), known to cause at least 16 severe or life-threatening medical conditions including visual impairment that leads to early blindness, severe life-limiting obesity, learning difficulties, life-threatening kidney abnormalities and more.

The Axovia journey so far: 

  • 2020: the spinout was founded 

     

Team

Professor Phil Beales

Founder and CEO

Professor Beales is a leading scientist and diagnostic expert in ciliopathies, spearheading the most comprehensive research and clinical effort on Bardet-Biedl syndrome (BBS).

Dr Rick Fagan

Dr. Rick Fagan

Director of BioPharm

Institute of Clinical Trials and Methodology

Dr. Fagan brings extensive cell biology, pharma and technology transfer leadership experience, including AstraZeneca, SanofiAventis and UCL Ventures. He holds a PhD from McGill University.